JASPER THERAPEUTICS, INC. (JSPR) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -55.16M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 36.70M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-55.16M | (m) | (m) | $36.70M | (m) | (m) |
| 2026-03-31 | $-73.03M | (m) | (m) | $52.76M | (m) | (m) |
| 2025-12-31 | $-83.88M | (m) | (m) | $63.10M | (m) | (m) |
| 2025-09-30 | $-93.33M | (m) | (m) | $71.52M | (m) | (m) |
| 2025-06-30 | $-94.05M | (m) | (m) | $71.58M | (m) | (m) |
| 2025-03-31 | $-82.97M | (m) | (m) | $61.68M | (m) | (m) |
| 2024-12-31 | $-76.24M | (m) | (m) | $55.82M | (m) | (m) |
| 2024-09-30 | $-68.68M | (m) | (m) | $49.88M | (m) | (m) |
| 2024-06-30 | $-68.15M | (m) | (m) | $50.28M | (m) | (m) |
| 2024-03-31 | $-69.99M | (m) | (m) | $52.28M | (m) | (m) |
| 2023-12-31 | $-68.86M | (m) | (m) | $51.78M | (m) | (m) |
| 2023-09-30 | $-64.88M | (m) | (m) | $47.23M | (m) | (m) |
| 2023-06-30 | $-58.23M | (m) | (m) | $41.41M | (m) | (m) |
| 2023-03-31 | $-52.37M | (m) | (m) | $36.24M | (m) | (m) |
| 2022-12-31 | $-51.20M | (m) | (m) | $34.63M | (m) | (m) |
| 2022-09-30 | $-49.53M | (m) | (m) | $34.00M | (m) | (m) |
| 2022-06-30 | $-46.90M | (m) | (m) | $32.17M | (m) | (m) |
| 2022-03-31 | $-43.36M | (m) | (m) | $29.19M | (m) | (m) |
| 2021-12-31 | $-36.83M | (m) | (m) | $25.42M | (m) | (m) |
| 2021-09-30 | $-10.96M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-24 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-1.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-921.14K | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-935.40K | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-11-21 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-08-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |